A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting

Radiolabelled bisphosphonates are commonly used in the diagnosis and therapy of bone metastases. Blood clearance of bisphosphonates is usually fast and only 30 –50% of the injected activity is retained in the skeleton, while most of the activity is excreted by the urinary tract. A longer blood circulation may enhance accumulation of bisphosphonate compounds in bone metastases. Therefore, a chemically modified macrocyclic bisphosphonate derivative with an additional human albumin binding entity was synthesized and pharmacokinetics of its complex was evaluated.
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Source Type: research